Finance

BioShield's Wraps Up 2001 With Contracts Totaling $55 Million Over Next Five Years

Published in TB and Outbreaks Week, January 22nd, 2002

BioShield Technologies, Inc., (BSTI) has announced that a strong calendar year resulted in a better-than-expected backlog of revenues from signed contracts for the company's core antimicrobial products totaling $55 million over the next five years.

With this increase in revenues, gross profits will continue to remain at high levels. The steady growth of BioShield's sales over the past year (reflecting 50% quarterly growth rates) and growing acceptance of its products in worldwide markets is expected by management to continue returning a high growth rate over the upcoming year.

Over the course of the year, the company adjusted expenses in line with...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week

Source: TB and Outbreaks Week (2002-01-22)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry